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Summary. Prophylaxis of bleeding from esophage- 
al varices is a very tempting concept at first glance, 
especially under the assumption of a high mortality 
associated with first variceal hemorrhage. Up to 
now four different measures have been tried for 
prophylaxis: portacaval shunt operation, devascu- 
larization procedures, sclerotherapy, and drugs. 
With the exception of portacaval shunts, ongoing 
controlled trials show a weak trend toward reduc- 
tion of variceal bleeding and prolongation of sur- 
vival in selected patients with compensated cir- 
rhosis and large varices. However, prophylaxis of 
first variceal bleeding must still be regarded as ex- 
perimental and should be restricted to controlled 
clinical studies. 
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Although variceal hemorrhage in patients with 
liver cirrhosis may be life threatening, prophylaxis 
of variceal bleeding is still a matter of controversy. 
The decision to initiate prophylactic regimens de- 
pends as much on the knowledge about epidemio- 
Iogy and pathogenesis of variceal bleeding as on 
the results of controlled trials with respect to both 
the beneficial and adverse ffects. 
Epidemiology of First Varieeal Bleeding 
Thirty to seventy percent of patients with liver cir- 
rhosis develop esophageal v rices [14], but only 
20%-40% of these patients bleed from their var- 
ices during a follow-up period of about 2 to 
14 years [1, 15, 16, 35, 67]. Overall mortality of 
first variceal hemorrhage was 50% in the Copen- 
hagen study [89]. However, it largely depends on 
Abbreviations: ICG = Indocyanine-green; WHVP/FHVP-gra- 
dient :Wedged hepatic venous pressure minus free hepatic ve- 
nous pressure gradient 
hepatic function. In the Royal Free Hospital of 
London [8], only 33% of 198 cirrhotics died within 
6 weeks after first variceal bleeding (Child A and 
B 12%, Child C 61%). In our own setting, the 
6 months' mortality in patients with active bleed- 
ing (n=116) was 12% in Child's group A and B 
and 64% in Child's group C [74]. The risk of death 
from variceal bleeding may be calculated as 
3%-5% per year in patients with liver cirrhosis 
and proven esophageal varices [90]. 
Pathogenesis of Varieeal Bleeding 
Hemodynamic Parameters 
It is widely accepted that the rupture of any vessel 
is due to an increase in tension of the vessel's wall 
overriding its elastic and mechanical properties. 
According to La Place's law, tension of the wall 
equals the product of the radius of the tube and 
the transmural pressure, whereas it is inversely re- 
lated to the thickness of the wall [45]. Therefore, 
parameters which are involved in the pathogenesis 
of variceal hemorrhage must influence the diame- 
ter, the transmural pressure gradient, properties 
of the wall of the varices, or a combination of 
those. 
When thinking of pressure parameters which 
might increase the risk of variceal hemorrhage, it 
is more logical to look at pressure gradients than 
at the absolute blood pressure in the vessels. This 
has been understood only lately. Esophageal var- 
ices are fed by the venous portal system lying in 
the relatively high pressure zone of the abdomen 
and drain into the relatively low pressure zone of 
the thoracic venous system. During deep inspira- 
tion this abdomino-thoraCic pressure gradient in- 
creases and approximates as much as 40 mmHg 
[14]. Thus, respiration may significantly influence 
variceal blood flow, transmural varix pressure, and 
the risk of variceat hemorrhage [14, 65]. 
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Most of the esophageal varices rupture at or 
just above the gastroesophageal junction [54, 84]. 
Variceal pressure at this point is presumably identi- 
cal or only slightly inferior to portal pressure, while 
the intraesophageal pressure probably comes close 
to the relatively low intrathoracic pressure. There- 
fore, the intravascular pressure of the collaterals 
in this region is no longer counteracted by the high 
intraabdominal pressure surrounding the vessel. 
Hemodynamic studies undertaken to date have 
investigated the possible roles of portal pressure, 
variceal pressure, and of azygos blood flow in de- 
termining variceal hemorrhage. 
Portal Vein Pressure 
Besides the direct assessment of portal vein pres- 
sure by direct cannulation [14, 60] the pressure 
gradient of wedged hepatic venous pressure minus 
free hepatic pressure (WHVP/FHVP gradient) has 
been used in most studies since it approximates 
closely the portal venous pressure at least in alco- 
holic cirrhosis [7]. In nonalcoholic irrhosis this 
pressure gradient may be slightly lower than the 
portal venous pressure [7]. 
In several retrospective studies there was no 
significant difference in the WHVP/FHVP gra- 
dient between patients with and without previous 
variceal hemorrhage [18, 40, 70, 93]. Analysis of 
the available data shows that the WHVP/FHVP 
gradient in patients with previous variceal hemor- 
rhage was nearly always higher than 12 mmHg. 
However, according to recent observations [25, 
92], this is the threshold for the appearance of 
esophageal varices rather than an indicator for 
their rupture. 
It may be derived from these studies that after 
assessment of esophageal varices by more simple 
means (e.g., endoscopy), portal pressure measure- 
ments have a limited value for the prediction of 
variceal hemorrhage. For the individual patients, 
however, these data do not contradict the hypothe- 
sis that lowering portal pressure will reduce the 
risk of hemorrhage. 
Esophageal Variceal Pressure 
Portal pressure may not relate closely to intravari- 
ceal pressure owing to variable resistances inter- 
posed between the two veins [69]. Therefore, 
knowledge of esophageal variceat pressure is im- 
portant [27]. In earlier studies by Palmer and Brick 
[56] intravariceal pressure was not significantly 
correlated to the risk of variceal hemorrhage. 
However, recently Staritz et al. have found [82, 83] 
a significantly higher variceal pressure in patients 
with previous variceal bleeding than in those with- 
out bleeding (227 vs 16 mmHg). The same group 
also showed a higher pressure in large rather than 
small varices. The esophageal lumen was taken as 
reference pressure by these authors. 
Azygos Blood Flow 
Measurement of azygos blood flow by thermodilu- 
tion [5, 6] showed a significant correlation with 
variceal pressure and variceal size. However, no 
significant correlation with the bleeding risk could 
be demonstrated [10]. The azygos vein carries not 
only blood from the intraesophageal varices (the 
only vessels exposed to rupture), but also from the 
periesophageal varicosities and from other veins 
in the thorax. This may explain why a correlation 
with the bleeding risk was not found 
Histological and Endoscopic Parameters 
Esophagit& 
Endoscopic studies on the prevalence of esophagi- 
tis in patients with and without variceal bleeding 
are controversial [3, 45, 46, 54, 61, 62, 79-81]. 
Most of these studies found no good correlation 
between the endoscopic finding of reflux esophagi- 
tis and history of bleeding [64]. Therefore, this is 
probably not an important risk factor. Using long- 
term pH monitoring, we found no significant dif- 
ference of the percentage of acid gastroesophageal 
reflux between patients with and without prior 
bleeding as well as between cirrhotics with and 
without varices (unpublished observations). This 
fact underlines the minor role of acid reflux [19, 
46] for pathogenesis of variceal bleeding provided 
there is no enhanced susceptibility of the mucosa 
in patients with varices. Furthermore, histological 
studies of esophageal rings obtained during tran- 
section and stapling of variceal bleeding showed 
no evidence of esophagitis [62, 79, 81]. 
Red Color Sign 
Certain endoscopically visible mucosal changes on 
top of the varices [3, 30], called cherry red spots, 
hematocystic spots or varix on varix are summa- 
rized as the red color sign by the Japanese Society 
of Portal Hypertension. This red color sign is asso- 
ciated with a history of bleeding in up to 100% 
of the patients when evaluated retrospectively [3]. 
However, so far no prospective study has estab- 
lished the sensitivity and specificity of this sign for 
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the prediction of bleeding. In addition, there are 
no data on the association of this sign with other 
parameters such as size of varices or hepatic func- 
tional status. It is thought hat the red color sign 
corresponds histologically to dilated intraepithelial 
or subepithelial blood filled vascular channels 
which are connected to submucosal varices. There 
were significantly more and larger channels visible 
in patients with portal hypertension than in a con- 
trol population [53, 80, 81] 
Variceal Size and Number 
As derived from La Place's law, the diameter of 
varices directly determines the tension of the vessel 
and therefore the risk of its rupture. Initial disten- 
sion of the venous vessel needs a relatively high 
increment of pressure. On the other hand, in large, 
thin-walled vessels a small pressure rise suffices for 
a further dilatation of the varix up to its rupture. 
According to Ohm's law, this pressure rise requires 
a higher blood flow in vessels with a large diameter 
than in vessels with a small diameter. 
The theoretical considerations mentioned 
above are in line with retrospective studies [1, 17, 
25, 34, 40, 56] which revealed that the bleeding 
risk of large varices is about three times higher 
than that of small varices. In fact, variceal size 
is the best documented risk factor for variceal 
bleeding. 
Ascites and Liver Function 
Ascites increases the abdominal and therefore the 
portal pressure with a subsequent increase in the 
thoracal abdominal pressure gradient. This may 
cause a higher bleeding risk. In the first study on 
prophylactic portacaval shunt operation [15] as- 
cites was present at time of inclusion in all patients 
who experienced variceal hemorrhage later on. 
However, this strong correlation between ascites 
and the risk of first variceal hemorrhage has not 
been found by others. It should be noted that to- 
gether with an intraabdominal pressure rise caused 
by ascites, resistance of the portal collateral system 
may also increase and may blunt the transduction 
of increased portal pressure to transmural variceal 
pressure. 
A number of other parameters related to the 
hepatic functional status such as jaundice or a low 
prothrombin time may predict an increased bleed- 
ing risk. A disturbed liver function could also influ- 
ence other ill-defined hemostatic factors which 
contribute to the pathogenesis ofvariceal bleeding. 
On the other hand, a significant proportion f pa- 
tients with good liver function (Child A) bleed 
from their varices [8, 73, 74]. 
In summary, size and number of varices are 
probably the best-defined parameters for the pre- 
diction of first variceal hemorrhage. However, for 
the initiation of prophylactic measures it is very 
important to have more information on sensitivity, 
specificity, and predictive value of these parame- 
ters in relation to predicting variceal hemorrhage. 
Prophylaxis of First Varieeal Bleeding 
Early reports [12, 68] showed an enormous 
30%-80% mortality associated with variceal hem- 
orrhage. Therefore, prophylaxis is a very tempting 
concept at first glance. Up to now four different 
therapeutic measures have been tried for prophy- 
laxis of variceal bleeding: portacaval shunt opera- 
tion, devascularization procedures, sclerotherapy, 
and drugs. Yet, at the moment, none of these regi- 
mens has become the therapy of choice for preven- 
tion of first variceal bleeding. 
Prophylactic Shunt Operations 
When it had been shown that portacaval shunts 
efficiently reduce the variceal bleeding risk, the 
question arose whether this procedure should be 
carried out as a prophylactic measure. Four ran- 
domized controlled trials [15, 16, 31, 67] have been 
carried out in the 1960s and early 1970s. All of 
these studies showed that despite preventing vari- 
ceal hemorrhage, prophylactic shunts failed to pro- 
long survival [11]. On the contrary, there was even 
a trend to diminution of survival after the opera- 
tion despite the virtual elimination of hemorrhage 
from esophageal varices. The control groups com- 
prised a total of 160 patients and the shunt groups 
130 patients [11]. During a follow-up period of 5 
to 14 years, 44% of the patients died in the non- 
operated and 58% in the shunted group. The per- 
centage of first variceal bleeding in the control pa- 
tients and in the patients who had refused treat- 
ment ranged between 20% and 40%. The lack of 
a positive ffect of the portacaval shunt on survival 
was mainly attributed to operative mortality and 
increased long-term mortality due to hepatic fail- 
ure in the shunted patients after loss of portal 
blood supply of the liver. Therefore, a logical ap- 
proach to prophylactic operation would be a meth- 
od that significantly reduces the risk of variceal 
bleeding with low operative mortality and mainte- 
nance of portal blood flow. Devascularization pro- 
cedures and sclerotherapy fulfill these require- 
ments. 
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Devascularization Procedures 
In Japan, nonshunting operations and selective 
shunts are carried out as a standard operation with 
satisfactory clinical results. Inokuchi et al. [30] 
published an interim report on prophylactic portal 
nondecompressing surgery in patients with esopha- 
geal varices. All patients had no prior variceal 
bleeding, although patients with a history of bleed- 
ing of nonvariceal origin were included. Etiology 
of cirrhosis was nonalcoholic in most of the pa- 
tients and the varices were of at least moderate 
size with local potential risk factors such as cherry 
red spots [3]. Child C patients were omitted. The 
nonoperative group comprised 52 patients and the 
operated group 60 patients. Fifty of these received 
operations causing direct interruption of the var- 
ices (e.g., transection) and 10 selective shunts. Dur- 
ing a follow-up of 24 months, the cumulative death 
rate was 17% in the operated group and 30% in 
the controls. The survival curves were not signifi- 
cantly different. The cumulative bleeding rate in 
the nonoperated patients was 32%, while none of 
the operated patients bled. Mortality rate for the 
first bleeding event in the controls was 50%. About 
half of the deaths in the nonoperated group was 
due to bleeding. The authors speculate that non- 
portal decompression surgery may also achieve a 
significant improvement in survival when a longer 
follow-up has been studied. 
Prophylactic Sclerotherapy 
The need for prophylactic sclerotherapy has been 
debated since results of two controlled trials were 
published [57, 95]. In both trials, the control group 
received only conservative management, that is, 
balloon tamponade and/or vasopressin i case of 
bleeding. First variceal hemorrhage occurred in 
66% and 57% of the controls vs 6% and 9% in 
the prophylactically treated patients during a fol- 
low-up period of up to 5 years. Also the survival 
rate was significantly reduced in the controls (42% 
vs 6% and 55% vs 21%) as compared with the 
prophylactically treated patients. However, both 
trials found a considerably higher incidence of first 
variceal hemorrhage in the control group than 
other studies [1, 15, 3t, 67], a fact which is difficult 
to explain. Paquet [57] selected patients with large 
varices and/or clotting abnormalities while Witzel 
and coworkers [95] made no selection concerning 
hepatic function status or size of varices. As con- 
cerns etiology, no data are given in Paquet's paper. 
In Witzel's study about 80% of the patients had 
alcoholic disease. Were there other local factors 
such as presence of the red color sign that increased 
the risk of bleeding? In Paquet's tudy these factors 
were present in most of the patients. The other 
study does not consider this point. According to 
our own observations [34] these local factors are 
only of minor importance as compared with size 
and number of varices. 
With regard to risk-benefit considerations the 
complications of prophylactic sclerotherapy have 
to be kept in mind. They can be divided into those 
occurring at the site of injection (mostly ulcera- 
tions and esophageal fibrosis [20]) and into those 
originating from injection and systemic dissemina- 
tion of the sclerosant (mostly fever, bacteremia [72, 
76], or pulmonary side effects [32, 52, 71]). In pro- 
spective therapeutic clinical trials [38, 47, 58, 73, 
77, 78, 87-89, 94] fatal complications ranged be- 
tween 0% and 13% (median 2.5%), mostly caused 
by perforation of the esophagus, aspiration pneu- 
monia, and bleeding esophageal ulcers. Although 
the risk of fatal complications i supposed to be 
lower in patients undergoing elective sclerothera- 
py, it has to be kept in mind that 1% to 2% of 
the patients may die by endoscopic prophylaxis. 
Bleeding ulcerations are observed in up to 15% 
in the therapeutic studies (median 9%). In other 
words it is highly improbable that prophylactic 
sclerotherapy reduces the bleeding risk to zero be- 
cause 5% to 10% of the patients who never bled 
may exhibit bleeding induced by sclerotherapy. In
addition, some patients may bleed from gastric 
varices occurring in 10% to 20% of patients with 
esophageal varices. Hemorrhage from gastric var- 
ices cannot be prevented by prophylactic sclero- 
therapy. 
If we assess ample size requirements for a pro- 
phylactic sclerotherapy trial by assuming from the 
literature that about 30% of the control popula- 
tion will bleed frorn varices and if we assess that 
the risk is to be reduced by sclerotherapy from 
30% to 10%, about 70 patients are required in 
each group in order to obtain a statistically signifi- 
cant difference with a type I error of 5% and a 
type II error of 20%. If the bleeding risk is to be 
reduced from 30% to 15% by sclerotherapy, a 
number of 125 patients is needed in each group. 
These figures show that the proof of a beneficial 
effect of sclerotherapy, if present, requires a large 
number of patients. Selection of patients with a 
considerable bleeding risk may allow sclerotherapy 
to be used where its benefits are more certain and 
require smaller sample sizes in controlled trials. 
During a symposium on prophylaxis of variceal 
hemorrhage at our department in January 198Q 
apart from the studies already published [57, 95], 
preliminary results on prophylactic sclerotherapy 
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were presented [21, 24, 29, 36, 75, 96]. If we com- 
bine these results, a total of 339 patients without 
previous gastrointestinal b eeding were reported 
on. In this group 162 patients were randomized 
to sclerotherapy and 177 to no prophylactic treat- 
ment. Follow-up ranged from a few months to 
7 years. Most centers elected patients with large 
varices and when bleeding occurred most of the 
patients received sclerotherapy. Bleeding occurred 
in 22% of the sclerotherapy group and in 35% 
of the controls. The mortality rate was 28% in 
the sclerotherapy atients and 35% in the controls. 
None of these preliminary individual studies found 
a statistically significant improvement of survival 
and only one study [96] showed a significantly re- 
duced bleeding rate after sclerotherapy. None of 
the studies found a higher bleeding risk after initia- 
tion of sclerotherapy. All studies suffered from a 
relatively small number of patients. In the final 
discussion the panel agreed that prophylactic scle- 
rotherapy should only be carried out within con- 
trolled trials [86]. 
Beta-Blockers for Prophylaxis 
of First Variceal Hemorrhage 
Beta-adrenoceptor blocking agents cause a reduc- 
tion in portal blood flow leading to a moderate 
decrease of portal hypertension [5, 39, 42]. This 
effect is probably achieved by a reduction of cardi- 
ac output together with splanchnic vasoconstric- 
tion [42]. Based on these hemodynamic studies, 
prolonged oral therapy with beta-blockers was 
used to lower portal pressure [41, 43] and to pre- 
vent recurrent variceal bleeding. Three different 
types of beta-adrenoceptor blocking agents were 
used: substances that preferably bind to beta I re- 
ceptors and reduce cardiac output, such as atenolol 
[28], agents that selectively interact with beta 2 re- 
ceptors (these receptors are found in the peripheral 
and splanchnic irculation), causing splanchnic va- 
soconstriction [4, 33, 39], and nonselective beta- 
blockers that influence both beta 1 and beta 2 re- 
ceptors [42]. Most clinical experience in cirrhotic 
patients with portal hypertension has been ob- 
tained with the nonselective beta-blocker propran- 
olol. Lebrec's [41, 43] report of a significant de- 
crease of gastrointestinal rebleeding events after 
continuous oral administration ofpropranolol was 
not confirmed by Burroughs et al. [9]. Explana- 
tions for these discrepant results might be differ- 
ences in etiology or severity of cirrhosis, selection 
or randomization bias or possibly a reduced hemo- 
dynamic response to propranolol due to down reg- 
ulation of beta-adrenoceptors in decompensated 
cirrhotics who were included in the British, but 
not in the French study [11, 26, 50]. 
There are several well-known side effects of 
chronic beta-blocker therapy such as Raynaud's 
phenomenon, peripheral ischemia, dyspnea, impo- 
tence, lethargy or skin disorders, which range be- 
tween 1% and 10% [48]. In addition to these side 
effects, impairment of renal or liver function due 
to a reduction of hepatic perfusion [5] with precipi- 
tation of hepatic encephalopathy [85, 91] and a 
decreased natriuretic effect of diuretics in patients 
with liver cirrhosis [63] have been suggested. The 
frequency of these side effects is still a matter of 
controversy [2, 5] and their relevance will depend 
on the benefits of prophylactic beta-blockade 
which may be shown in ongoing trials. 
At present, there are only few data on beta- 
blockers for the prophylaxis of first variceal hem- 
orrhage. Several prospective randomized trials 
have been started [44, 55, 59]. When combined, 
a total of 456 patients were included in these trials. 
Of these 225 were assigned to beta-blockers and 
231 to placebo. It is rather difficult to draw any 
definite conclusions from these preliminary results. 
Only nonselective blockers, propranolol [55, 59] 
or nadolol [23, 44] have been administered. Pa- 
tients with end-stage cirrhosis (Child-Pugh score 
above 13) were not included in any of these studies. 
In one study, a vast majority (90%) were alcoholic 
cirrhotics [59]. The other study [55] comprised 
40% alcohol-induced cirrhosis and no data on the 
etiology of cirrhoses are available from the third 
trial [44]. A wide range of about 20% [59] to 80% 
[55] of the consecutively observed patients were 
included in the studies. Thus, differences in severity 
and etiology of cirrhosis as well as selection bias 
will have to be discussed once the final results of 
these prophylactic trials are presented. At the pres- 
ent stage, the following preliminary results can be 
derived from the ongoing trials: An overall reduc- 
tion of first bleeding events was observed in se- 
lected groups of compliant patients with compen- 
sated cirrhosis in two studies [44, 55]. However, 
contrary to these trials and to the studies on pre- 
vention of rebleeding, Pascal et al. [59] presented 
a reduction of first variceal hemorrhage and pro- 
longed survival especially in Child C patients. 
Nonselective beta-blockers may reduce the 
bleeding risk in compliant patients. However, at 
the moment he selection of patients in whom sur- 
vival and risk of bleeding may be improved (alco- 
holic or nonalcoholic irrhotics, compensated or
decompensated cirrhotics) is unclear. It is still 
questionable whether beta-blocker prophylaxis re- 
ally offers an overall benefit. 
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When patients, in whom treatment was stopped 
because of side effects or noncompliance are in- 
cluded in the calculations, the beneficial effect of 
beta-blocker therapy probably cannot be proved. 
Patients who stopped treatment may have an in- 
creased risk of bleeding, possibly due to a rebound 
effect at upregulated receptors. 
In conclusion, prophylactic treatment with 
beta-blockers might turn out to be beneficial for 
selected patients with large varices who do not ex- 
hibit contraindications to beta-blockers and who 
are compliant. At present, however, beta-blockade 
for prophylaxis of variceal hemorrhage of cirrhot- 
ics should be limited to controlled trials. 
Other Drug Candidates for Prophylaxis 
of Variceal Bleeding 
The pressure gradient in a vessel is proportional 
to flow and resistance [66]. Acute and chronic 
pharmacotherapy of portal hypertension in its 
present state is carried out with beta-blockers, va- 
sopressins, or somatostatin which lower portal 
pressure by decreasing portal venous flow. This 
theoretically may worsen liver function. Therefore, 
according to Reichen [66], the ideal portal antihy- 
pertensive agent should have the following proper- 
ties: high first-pass extraction to maximize hepatic 
and minimize systemic effects after oral admini- 
stration, in order to act by decreasing portal resis- 
tance rather than flow and by this maintain or 
improve hepatic function. Candidates which might 
fulfill these criteria include nitrates [22] and calci- 
um antagonists [37, 50, 51, 66]. While nitrates de- 
crease hepatic blood flow, the calcium antagonists 
may increase hepatic blood flow at least in oncirr- 
hotic humans [51]. It has been shown in rats with 
alcoholic liver damage that the calcium antagonist 
verapamil which has a much higher first-pass effect 
than nifedipin improves blood flow and hepatic 
function and ecreases splenic pulp pressure. Also 
in man (nine cirrhotic patients) verapamil (50 mg 
per os) improved the ICG clearance without affect- 
ing pulse rate or systemic blood pressure [50, 51, 
66]. According to Reichen [66] this effect of vera- 
pamil might be explained by an action on the he- 
patic microvascular bed by decreasing intrahepatic 
shunting and redistributing blood flow into sinus- 
oids with better exchange characteristics. There- 
fore, clinical trials on the prophylactic effect of 
verapamil n patients with portal hypertension and 
esophageal varices seem to be reasonable. With 
regard to portal hypertension and liver function 
alpha-adrenocepter blocking agents may be further 
candidates [49]. 
Already more than 25 years ago [45] it had 
been shown that diuretics may reduce portal pres- 
sure, possibly due to a reduction of the plasma 
volume [97]. In this context recent findings on low- 
ering portal pressure by chronic application of 
spironolactone are interesting [35] and warrant 
further confirmation. 
Conclusions 
Prophylaxis of first variceal hemorrhage has two 
major aims: first, improvement of survival and sec- 
ond, reduction of the bleeding risk with improve- 
ment of life quality. Prophylactic measures may 
theoretically improve life quality by reducing the 
risk of variceal bleeding in patients with good or 
moderate hepatic functional status (Child A and 
B), provided the regimen is not too aggressive. 
However, in these patients it is questionable wheth- 
er it prolongs urvival. Most of them will not die 
from the first bleeding event. On the other hand, 
hemorrhage in patients with bad functional status 
(Child C) may be life threatening and prevention 
of bleeding could lead to an improvement of sur- 
vival in this group. Yet, especially these patients 
may be very susceptible to adverse ffects of pro- 
phylactic regimens and their life quality might suf- 
fer badly. Furthermore, it is highly questionable 
whether Child C patients with end-stage liver dis- 
ease, in whom bleeding is more a complication 
than cause of terminal illness, will profit from any 
prophylactic regimen. 
From the controlled trials on prophylaxis of 
variceal bleeding we may draw the following con- 
clusions: 
Prophylactic portacaval shunt operations have 
been abandoned although they lower the bleeding 
risk by 90% because survival may be reduced by 
the operation. 
Nonportal decompression surgery (mostly 
esophageal transection) is a relatively safe opera- 
tion in Japan reducing the bleeding risk as effec- 
tively as portacaval shunt operations, but with a 
lower early and late mortality. This procedure 
might have a beneficial effect on survival in com- 
pensated nonalcoholic cirrhotics with large varices. 
However, the results have been obtained in a Japa- 
nese population and need to be reproduced in 
Western countries. 
Prophylactic sclerotherapy reduces the bleeding 
risk to a lesser extent than portacaval shunts or 
the Japanese transection procedures. Most trials 
showed a trend toward prolongation of survival. 
However, in several recent studies this effect is not 
impressive. 
Although most trials selected patients with high 
bleeding risk, mostly based on the finding of large 
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varices, the cumulat ive percentage of  hemorrhage  
in the contro ls  was only about  30%. This means 
that  about  70% o f  the patients were treated unne-  
cessarily. Therefore,  further  research should focus 
on ep idemio logy and pathogenesis  o f  variceal 
bleeding for  better identi f icat ion o f  patients who 
might  benefit  f rom prophylaxis .  At  the moment ,  
variceai size is still the best predictor  o f  variceal 
bleeding. However ,  in the future, other parameters  
may be defined. 
In  the ongo ing  studies patients randomized  to 
beta-blockers,  c lerotherapy, o r  t ransect ion did not  
fare worse than the controls.  Therefore,  it appears  
justif ied to cont inue these trials until statistically 
valid results are obtained.  Unti l  this goal is 
reached, present methods  for  prophylaxis  o f  first 
variceal bleeding must  be regarded as experimental  
and their appl icat ion should be restricted to con-  
trolled trials. Centers conduct ing  such studies 
should have some basic knowledge on et io logy and 
natura l  h istory o f  variceal hemorrhage  in the pop-  
ulat ion to be studied. Dur ing  the trial, endoscopic  
appearance o f  varices, adverse effects o f  the pro-  
phylact ic  measures,  f requency o f  fo l low-up visits, 
a lcohol  dr ink ing habits, and compl iance o f  these 
patients should be registered. Results o f  such fu- 
ture studies may provide a better basis for  selection 
o f  patients in whom prophylact ic  t reatment  is man-  
datory.  
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